Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients

Epilepsia

Volumn 58, Issue 1, 2017, Pages 123-127

  Treat, Lauren ^a   Chapman, Kevin E ^a   Colborn, Kathryn L ^b   Knupp, Kelly G ^a  

^a CHILDREN S HOSPITAL COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Antiepileptic drugs; Cannabidiol; Cohort studies; Epilepsy; Medical marijuana; Pediatric

Indexed keywords

ANTICONVULSIVE AGENT; MEDICAL CANNABIS; CANNABIDIOL; PLANT EXTRACT;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; ALERTNESS; ANTICONVULSANT THERAPY; ARTICLE; ATONIC SEIZURE; BENIGN CHILDHOOD EPILEPSY; CHILD; CHILD BEHAVIOR; CHILDHOOD ABSENCE EPILEPSY; COHORT ANALYSIS; COLORADO; DISEASE EXACERBATION; DRUG EFFICACY; DRUG USE; DRUG WITHDRAWAL; FOCAL EPILEPSY; GASTROINTESTINAL SYMPTOM; HUMAN; INFANT; LENNOX GASTAUT SYNDROME; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MOTOR PERFORMANCE; MYOCLONIC ASTATIC EPILEPSY; MYOCLONUS EPILEPSY; PARENTAL ATTITUDE; PRIORITY JOURNAL; SEVERE MYOCLONIC EPILEPSY IN INFANCY; SLEEP; SOCIAL PSYCHOLOGY; SOCIAL STATUS; SOMNOLENCE; TONIC CLONIC SEIZURE; TONIC SEIZURE; TREATMENT DURATION; TREATMENT RESPONSE; EPILEPSY; FEMALE; KAPLAN MEIER METHOD; MALE; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; UNITED STATES;

ADMINISTRATION, ORAL; ADOLESCENT; ANTICONVULSANTS; CANNABIDIOL; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; EPILEPSY; FEMALE; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; MALE; PLANT EXTRACTS; UNITED STATES;

EID: 85003936089     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.13617     Document Type: Article

References (25)

1. Hussain SA, Zhou R, Jacobson C, et al. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy Behav 2015;47:138–141.
2. Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav 2013;29:574–577.
3. Consroe P, Wolkin A. Cannabidiol–antiepileptic drug comparisons and interactions in experimentally induced seizures in rats. J Pharmacol Exp Ther 1977;201:26–32.
4. Geffrey AL, Pollack SF, Bruno PL, et al. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia 2015;56:1246–1251.
5. Jones NA, Hill AJ, Smith I, et al. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther 2010;332:569–577.
6. Friedman D, Devinsky O. Cannabinoids in the treatment of epilepsy. N Engl J Med 2015;373:1048–1058.
7. Hill AJ, Weston SE, Jones NA, et al. Delta(9)-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats. Epilepsia 2010;51:1522–1532.
8. Jones NA, Glyn SE, Akiyama S, et al. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure 2012;21:344–352.
9. Colasanti BK, Lindamood C 3rd, Craig CR. Effects of marihuana cannabinoids on seizure activity in cobalt-epileptic rats. Pharmacol Biochem Behav 1982;16:573–578.
10. Szaflarski JP, Bebin EM. Cannabis, cannabidiol, and epilepsy–from receptors to clinical response. Epilepsy Behav 2014;41:277–282.
11. Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 2016;15:270–278.
12. Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev 2012;6:CD009270.
13. Pavisian B, MacIntosh BJ, Szilagyi G, et al. Effects of cannabis on cognition in patients with MS: a psychometric and MRI study. Neurology 2014;82:1879–1887.
14. Honarmand K, Tierney MC, O'Connor P, et al. Effects of cannabis on cognitive function in patients with multiple sclerosis. Neurology 2011;76:1153–1160.
15. Swarztrauber K, Dewar S, Engel J Jr. Patient attitudes about treatments for intractable epilepsy. Epilepsy Behav 2003;4:19–25.
16. Available at: https://www.colorado.gov/pacific/cdphe/data. Accessed June 3, 2016.
17. Press CA, Knupp KG, Chapman KE. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav 2015;45:49–52.
18. Modi AC, Ingerski LM, Rausch JR, et al. Treatment factors affecting longitudinal quality of life in new onset pediatric epilepsy. J Pediatr Psychol 2011;36:466–475.
19. Loring DW, Meador KJ. Cognitive side effects of antiepileptic drugs in children. Neurology 2004;62:872–877.
20. Bourgeois FT, Olson KL, Poduri A, et al. Comparison of drug utilization patterns in observational data: antiepileptic drugs in pediatric patients. Paediatr Drugs 2015;17:401–410.
21. Broyd SJ, van Hell HH, Beale C, et al. Acute and chronic effects of cannabinoids on human cognition-A systematic review. Biol Psychiatry 2016;79:557–567.
22. Elger C, Halasz P, Maia J, et al. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 2009;50:454–463.
23. French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 2012;79:589–596.
24. Ng YT, Conry JA, Drummond R, et al. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology 2011;77:1473–1481.
25. Porter RJ, Burdette DE, Gil-Nagel A, et al. Retigabine as adjunctive therapy in adults with partial-onset seizures: integrated analysis of three pivotal controlled trials. Epilepsy Res 2012;101:103–112.